Meeting Banner
Abstract #3891

Detection of recurrent prostate cancer with 18F-Fluciclovine PET/MRI

Kirsten Margrete Selnæs1,2, Mattijs Elschot1, Brage Krüger-Stokke1,3, Håkon Johansen4, Per Arvid Steen3, Sverre Langørgen3, Bjørg Yksnøy Aksnessæther5, Gunnar Indrebø5, Torill Anita Eidhammer Sjøbakk1, May-Britt Tessem1, Siver Andreas Moestue1, Heidi Knobel6, Torgrim Tandstad6, Helena Bertilsson7,8, Arne Solberg6, and Tone Frost Bathen1,2

1Department of Circulation and Medical Imaging, NTNU- Norwegian University of Science and Technology, Trondheim, Norway, 2St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 3Department of Radiology, St. Olavs Hospital, Trondheim University Hospital, 4Department of Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, 5Ålesund sjukehus, Helse Møre og Romsdal HF, 6Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, 7Department of Urology, St. Olavs Hospital, Trondheim University Hospital, 8Department of Cancer Research and Molecular Medicine, NTNU- Norwegian University of Science and Technology, Trondheim, Norway

Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in one imaging session. The aim of this observational study is to assess the detection rate of recurrent prostate cancer by simultaneous 18F-Fluciclovine PET/MRI. We demonstrate that18F-Fluciclovine PET/MRI can detect suspicious lymph node, prostatic and bone lesions in patients with a wide range of PSA levels and that the number of equivocal findings is reduced when MR images are evaluated in conjunction with PET uptake. .

This abstract and the presentation materials are available to members only; a login is required.

Join Here